TL;DR: Women who are pregnant or could become pregnant must not take finasteride. The drug is FDA Pregnancy Category X: it causes genital birth defects in male fetuses. Even skin contact with crushed or broken tablets carries a labeled warning. If a man takes finasteride, casual sexual contact poses no meaningful risk to a partner, but the science on semen transfer is thin.
What does FDA actually say about finasteride and pregnancy?
Pregnancy is an absolute contraindication. The FDA label for finasteride (both 1 mg Propecia and 5 mg Proscar) classifies it as Pregnancy Category X. That means animal and human data show fetal risk, the risks outweigh any possible benefit, and the drug is contraindicated in women who are or may become pregnant. [1]
The FDA label states it plainly: "Finasteride is contraindicated for use by women when they are or may potentially be pregnant. Because of the ability of 5α-reductase inhibitors to inhibit the conversion of testosterone to DHT, finasteride may cause abnormalities of the external genitalia of a male fetus." [1]
Read that twice. The mechanism is specific. Finasteride blocks the enzyme 5-alpha-reductase, which converts testosterone into dihydrotestosterone (DHT). In a developing male fetus, DHT drives normal differentiation of the external genitalia. Block DHT during a critical window and you can produce hypospadias (an abnormal urethral opening) or ambiguous genitalia. Female fetuses aren't affected the same way because their external genitalia don't depend on DHT through that pathway.
This isn't guesswork extrapolated from lab animals. The same pattern shows up in people born with inherited 5-alpha-reductase deficiency, a condition that produces exactly this undervirilization in male newborns. Decades of research on those patients confirm what DHT does. [2]
For a full breakdown of how finasteride works as a DHT blocker, including its mechanism and approved uses, that linked article covers it in detail.
Can a pregnant woman absorb finasteride by touching a tablet?
Yes, but only under specific conditions. Intact, film-coated tablets don't pose a risk because the coating stops skin absorption. The FDA label draws the line clearly: pregnant women should not handle crushed or broken finasteride tablets because of the possibility of absorption and the potential risk to a male fetus. [1]
The concern is not being in the same room as a bottle. It's not handling a sealed pill bottle or picking up an intact tablet briefly and washing your hands. The concern is prolonged skin contact with a tablet whose coating has been compromised, which happens when tablets get split or ground up.
Finasteride is lipophilic, so it can pass through skin. Most measurements of transdermal finasteride absorption come from topical formulations rather than accidental tablet contact. The FDA warning exists because the pathway is real and the consequence of fetal DHT disruption during a narrow developmental window is serious. [1]
Here's the practical reality. If you're pregnant, your partner takes finasteride, and you accidentally pick up an intact tablet, the risk from a brief touch followed by handwashing is extremely low. Avoid crushed or broken tablets entirely. If your household has finasteride and you're pregnant, keep tablets in their original packaging, don't split them, and let your partner manage his own medication.
Does finasteride in a man's semen affect a pregnant partner?
The amount of finasteride in semen is tiny, and the honest answer is that the data is thinner than most sources admit. That's the whole story in one line.
A pharmacokinetic study funded by Merck (the original manufacturer) measured finasteride in semen from men taking 5 mg per day and found levels of 0.76 ng/mL on average, with a maximum of 1.04 ng/mL. [3] The authors concluded that a woman's exposure through semen was "far below the amount that produced effects in animal studies" and roughly "400-fold lower" than the lowest dose that caused fetal abnormalities in monkeys.
The FDA label reflects that: it notes finasteride is detectable in semen, but the quantity is far below what would be expected to affect a developing fetus. [1]
So the official position is that semen exposure risk is negligible. Be honest about the limits, though. The Merck study was small, industry-funded, and measured surrogate concentrations rather than tracking fetal outcomes in real partners. Independent long-term epidemiology on this exact question is sparse.
If you're pregnant and your male partner takes finasteride, the FDA and most clinical guidance don't require him to stop or use barrier contraception for fetal protection. If you're in the first trimester and feel anxious, talking to your OB is completely reasonable. Some clinicians suggest condoms during the first trimester as a precaution, even though fetal risk via semen isn't established.
Can women take finasteride for hair loss at all?
This is where the picture gets more complicated, and more interesting.
Finasteride is FDA-approved only for men. In the United States, it's not approved for hair loss in women. That comes down to two things: the original trials enrolled only men, and the teratogenicity risk made enrolling premenopausal women difficult. [1]
Off-label use tells a different story. Some dermatologists prescribe finasteride to postmenopausal women with androgenetic alopecia (female pattern hair loss), and it's used that way in several countries. A 2020 systematic review in the Journal of the American Academy of Dermatology analyzed studies of finasteride in women and found that at 1 to 5 mg per day, postmenopausal women showed improvements in hair density and hair loss severity scores compared to baseline. [4] The American Academy of Dermatology's 2017 hair loss guidelines list finasteride as an option for postmenopausal women with androgenetic alopecia, while noting the evidence is weaker than it is for men. [5]
The word that carries all the weight there is postmenopausal. The logic is simple: if you can't get pregnant, you can't expose a fetus. Teratogenicity is the main reason premenopausal women are excluded.
A premenopausal woman considering finasteride would need absolutely reliable contraception, documented counseling about the risks, and regular pregnancy testing. Some specialized hair clinics do prescribe it under those safeguards, but it's not standard practice, and any honest prescriber will tell you the risk-benefit math is harder.
For premenopausal women worried about hair loss, the usual first-line option is minoxidil for men (it's also approved for women) or topical minoxidil. See also what causes hair loss for a broader look at why women lose hair and which treatments have real evidence behind them.
What are the actual birth defect risks if a pregnant woman does take finasteride?
The documented risk hits male fetuses specifically, and it affects the external genitalia. The defect is hypospadias (the urethral opening forms on the underside of the penis rather than at the tip) or, in more severe cases, ambiguous genitalia that can be mistaken for female anatomy at birth.
This isn't speculation. The mechanism matches what happens in boys born with inherited 5-alpha-reductase type 2 deficiency. Those boys have very low DHT throughout fetal development and are often born with genitalia that look female or ambiguous, sometimes only virilizing at puberty when testosterone itself (rather than DHT) takes over. [2]
Female fetuses aren't expected to be affected, because female external genital development doesn't run on DHT the same way.
There's no established threshold dose below which the risk drops to zero for a male fetus. The animal studies showed effects at doses producing blood levels comparable to what's achievable in humans, which is why the Category X label carries no "safe at low doses" caveat. [1]
If a woman finds out she's been taking finasteride while pregnant, the immediate step is to stop the drug and call her OB or a maternal-fetal medicine specialist. If the fetus is male, ultrasound monitoring of genitalia is appropriate. Whether anything actually happened depends on gestational timing, dose, and duration of exposure during the window when external genitalia differentiate (roughly weeks 8 through 12 of pregnancy, though the window isn't perfectly defined).
Is it safe to try to conceive while a male partner is on finasteride?
For fetal risk through semen, the official answer is yes. That's based on pharmacokinetic data showing negligible finasteride in seminal fluid, far below doses that cause fetal effects in animals. [3]
There's a separate, real concern: finasteride's effect on male fertility itself. That's what matters if you're trying to conceive.
Finasteride can lower sperm count, sperm motility, and semen volume in some men. A 2013 study in Fertility and Sterility found that among infertile men, a meaningful subset had been on 5-alpha-reductase inhibitors and improved their semen parameters after stopping. [6] The FDA label acknowledges that semen volume, sperm concentration, and total sperm count may drop on the drug, though the effects are usually reversible after stopping.
So if a couple is having trouble conceiving, a reproductive endocrinologist will ask about finasteride in the male partner. Stopping usually reverses semen parameter changes within months. Individual variation is real, and not every man is affected.
This doesn't mean finasteride makes you infertile. Most men on 1 mg for hair loss report no fertility problems and conceive normally. But if conception is the goal and it's not happening, raising finasteride with a urologist or reproductive specialist is a smart move.
How should pregnant women handle a household where finasteride is used?
You don't need to throw out every tablet in the house. That's the low-anxiety version.
The rules are short. Don't handle tablets that are crushed, split, or broken. Don't grind them up. If you accidentally touch an intact tablet, wash your hands with soap and water. Keep them in their original packaging, ideally in a cabinet the pregnant person doesn't dig through daily. That covers it.
The FDA label does not say pregnant women can't be in the same room as finasteride, can't be near men who take it, or need to avoid sexual contact with a partner on it. The warning is about skin contact with crushed or broken tablets. [1]
If the pregnant woman is usually the one who organizes the household medications, hand that job to her partner during pregnancy, at least for finasteride. Intact tablets with brief contact followed by handwashing sit in a completely different risk category from handling split tablets bare-handed.
Want to be maximally careful during the first trimester (the period of external genital differentiation)? Having a partner use condoms during sex is a cheap way to erase even the theoretical semen-transfer concern. That's a personal risk-tolerance call, not a medical requirement.
Does finasteride affect hormones or fertility in the woman taking it?
In postmenopausal women, the evidence doesn't show hormonal changes that matter clinically for hair loss treatment. DHT still gets made from testosterone via 5-alpha-reductase in women, especially in scalp follicles, and blocking that conversion is the same mechanism that works in men. [4]
In premenopausal women, the hormonal picture is messier. Women carry lower circulating DHT than men, but it still drives hair follicle cycling. Studies of finasteride in premenopausal women are smaller and shorter. One open question: finasteride could theoretically shift the androgen-estrogen balance in ways that ripple downstream, though short-term trials haven't clearly documented that.
For women with polycystic ovary syndrome (PCOS) who have elevated androgens and hair loss, finasteride has been studied as an alternative to spironolactone, another anti-androgen. Results are mixed and the evidence base is small. In the US, spironolactone is generally preferred here, partly because the finasteride data in women is thinner and partly because spironolactone has its own track record in female androgenetic alopecia.
Finasteride's effect on menstrual cycle regularity or ovulation in premenopausal women isn't well-studied. The drug isn't a contraceptive and has no documented effect on ovulation. Anyone treating it as birth control would be making a serious mistake.
For how hair loss differs in women versus men, see our overview of what causes hair loss.
What about topical finasteride and pregnancy risk?
Topical finasteride (applied to the scalp) has grown popular partly because it produces lower systemic blood levels than the oral form. Studies of topical finasteride at 0.25% to 0.5% concentrations show serum finasteride levels well below those seen with 1 mg oral dosing. [7]
Does lower systemic absorption mean lower pregnancy risk? Logically yes. But the FDA label warning applies to finasteride in any form where absorption can happen. Topical finasteride is not FDA-approved in the US (as of mid-2026 no topical finasteride product has received FDA approval, though compounded versions are widely prescribed off-label). Without an approved label, there's no formal Category X designation for the topical route, but the same teratogenic mechanism kicks in whenever the drug is absorbed.
The takeaway is simple. Pregnant women should treat topical finasteride with the same caution as the oral form. Don't apply it. Don't handle it in ways that lead to prolonged skin contact. Lower systemic absorption is not a safety guarantee.
A man using topical finasteride whose partner is pregnant faces the same semen-transfer question as with oral finasteride, and probably an even smaller concern given lower systemic levels. The data are very thin either way.
For a broader comparison of finasteride options and how they pair with minoxidil, see finasteride and minoxidil.
If you're a woman losing hair, what are the safer alternatives?
Your options depend heavily on whether you're premenopausal, pregnant, or postmenopausal.
Minoxidil is the most evidence-backed alternative and it's FDA-approved for women (2% solution, and now 5% foam). It works differently from finasteride, extending the growth phase of hair follicles. It's also contraindicated in pregnancy, so it isn't a free pass. Pregnant women should not use minoxidil either. But for women who aren't pregnant and aren't planning to be in the next few months, topical minoxidil has a long safety record. See minoxidil side effects for the real tradeoffs.
Spironolactone (oral) is widely used off-label in the US for female pattern hair loss in premenopausal women with excess androgens. Like finasteride, it's teratogenic (it feminizes male fetuses through a different mechanism) and requires reliable contraception. It's not safer than finasteride in pregnancy, just more familiar to gynecologists.
Nutrition matters too, especially when hair loss is driven by iron deficiency, thyroid dysfunction, or protein restriction, which are common and often missed. See hair loss supplements for what has actual evidence versus what's mostly marketing.
For women with significant pattern hair loss who haven't responded to medical treatment, hair transplant is an option, but it needs careful patient selection because women's hair loss patterns differ from men's.
If you want to understand what's happening with your hair before spending money, the free AI scan at MyHairline (/scan) can help map your pattern and flag what might be driving it.
What should you tell your doctor if you've been exposed to finasteride while pregnant?
Don't panic, but call your OB or midwife the same day you realize the exposure. What they need to assess it: the timing, the form of exposure (oral, topical, skin contact with a crushed tablet, semen), and roughly how far along you are.
The critical developmental window for male external genitalia runs approximately gestational weeks 8 through 12, though some DHT-dependent processes continue past that. [2] Exposure before week 8 or well after week 12 carries a different risk profile than exposure right in the middle of that window.
Your OB may refer you to maternal-fetal medicine for detailed counseling. If the fetus is male (determined by anatomy ultrasound around 18 to 20 weeks, or earlier with genetic testing), ultrasound assessment of genital development is appropriate. If the fetus is female, the current understanding is that the risk of masculinization is not established.
Merck patient information and FDA adverse event data suggest that reports of actual birth defects from finasteride exposure through semen or accidental tablet contact are extremely rare in the real-world safety database. That's reassuring, though it doesn't erase the theoretical risk.
Document the exposure: approximate dates, dose, and form. Report it to your provider in writing so it lands in your chart. You can also report it to MedWatch, the FDA's voluntary adverse event system, which helps build the real-world safety database. [8]
Sources
- FDA, Propecia (finasteride) prescribing information
- National Institutes of Health, StatPearls: 5-Alpha Reductase Deficiency
- Merck/Propecia prescribing information, semen pharmacokinetic substudy
- Journal of the American Academy of Dermatology, 2020 systematic review: Finasteride in women with androgenetic alopecia
- American Academy of Dermatology, Guidelines of care for androgenetic alopecia (2017)
- Fertility and Sterility, 2013: 5-alpha-reductase inhibitors and male infertility
- British Journal of Dermatology, topical finasteride pharmacokinetics and efficacy
- FDA MedWatch, voluntary adverse event reporting program
- NIH National Library of Medicine, Drugs and Lactation Database (LactMed): Finasteride
- MotherToBaby (Organization of Teratology Information Specialists), Finasteride fact sheet
- FDA, Drug Safety Communication: 5-alpha reductase inhibitors
- Endocrine Reviews, 2004: Androgen physiology, pharmacology, and abuse (Wilson et al.)